BRAF and neoplasm: Preclinical studies demonstrated that PD-1/PD-L1 blockade was effective in reducing tumor growth [108] and, when anti-PD-1/PD-L1 antibody was administered in combination with a BRAF-inhibitor, it reduced tumor volume and prolonged survival in murine models [88].